Price and availability of Indian version of crizotinib capsules
Globally, crizotinib (Crizotinib) has become an important treatment for certain cancer types. Although the drug was not originally manufactured in India, demand for it is growing in the Indian market. However, it should be noted that there are currently no locally produced original or generic crizotinib drugs in India, but patients may be able to purchase this drug through imported channels in India. Generic drugs of crizotinib have been launched in many countries, such as Laos and Bangladesh. The generic drugs produced by pharmaceutical factories in these countries are highly similar to the original drugs in terms of ingredients, but there may be differences in price, specifications, etc.
Crizotinib, a targeted therapy drug, is mainly used to treat patients with non-small cell lung cancer (NSCLC) withALK (Anaplastic Lymphoma Kinase)-positive gene mutations and ROS1-positive metastatic NSCLC. By precisely inhibiting the abnormal signaling caused by these gene mutations, crizotinib can effectively block the growth and spread of tumor cells, thereby providing patients with more effective treatments. Crizotinib may also cause a range of side effects. Among them, digestive system discomfort such as nausea, vomiting, diarrhea, etc. are more common reactions. In addition, some patients may experience symptoms such as fatigue, weakness, or physical weakness.
In terms of price, the original drug of crizotinib is priced relatively high in both domestic and foreign markets, and may reach more than RMB 10,000 per box. Fortunately, in China, this drug has been included in the national medical insurance coverage, which means that patients who meet the indications can enjoy a certain price discount when purchasing. In overseas markets, drug prices may change due to exchange rate fluctuations and other factors. In addition, for those patients looking for a more economical option, the price of a box of generic crizotinib produced in China such as Laos or Bangladesh may be around RMB 2,000, which undoubtedly provides them with a more affordable treatment option.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)